Further, our analyses revealed that some APS-high cases that did not exhibit a RUNX1 or TP53 variant also showed increased PTK2 expression, suggesting that transcriptome-based testing, in addition to better risk stratification, could permit better selection of therapies for myeloid malignancies. The gene discussed is RUNX1; the disease is autoimmune polyendocrinopathy.